**Innovation in central venous access device security: a pilot randomized controlled trial in
pediatric critical care**

Short title: RCT of CVAD security

Authors: Amanda J Ullman^{1,2,3}, Debbie Long^{1,3}, Tara Williams³, Kylie Pearson³, Gabor Mihala^{1,4,5}, Adrian C Mattke^{3,6}, Fiona Macfarlane^{3,6}, Claire M Rickard^{1,2},

Affiliations:

¹Alliance for Vascular Access Teaching and Research, Menzies Health Institute Queensland, Griffith University, Nathan, Queensland, Australia 4111

²School of Nursing and Midwifery, Griffith University, Nathan, Queensland, Australia 4111

³Paediatric Critical Care Research Group, Queensland Children's Hospital, South Brisbane Queensland, Australia 4101

⁴Centre for Applied Health Economics, Menzies Health Institute Queensland, Nathan, Queensland, Australia 4111

⁵School of Medicine, Griffith University, Nathan, Queensland, Australia, 4111

⁶Child Health Research Centre, University of Queensland, South Brisbane, Queensland, Australia 4101

Address correspondence to: Dr Amanda Ullman, School of Nursing and Midwifery, Menzies Health Institute Queensland, Griffith University, N48 Kessels Road, Nathan, Queensland 4111, Australia. Tel: +61 (0)7 3735 6462; Email: a.ullman@griffith.edu.au

Acknowledgements: We would like to thank the clinicians, parents and patients who participated in the study. We would also like to thank the other members of the Alliance for Vascular Access Teaching and Research (AVATAR) group for their support and guidance throughout this project.

Conflicts of interest statement:

Copyright form disclosure: Dr. Ullman's institution has received an unrestricted research grant from Centurion Medical Products (dressing manufacturers) to support research, 3M (dressing manufacturers) to support research, Becton Dickinson (dressing manufacturers) to support research. Drs. Ullman and Rickards' institutions received investigator-initiated grants, or consultancy payments on behalf of CMR from vascular access product manufacturers (3M, Adhezion, Angiodynamics, Bard, Baxter, Becton Dickinson, B Braun, Centurion Medical Products, Entrotech, Medtronic, and Smiths Medical). Dr. Long's institution received funding from Griffith University (payment for recruitment and data entry). The remaining authors have disclosed that they do not have any potential conflicts of interest.

Funding source: This research was independently developed and undertaken, without financial support from commercial industry or research grants.

ABSTRACT

Objective Central venous access devices (CVADs) enable many treatments during critical illness, however 25% of pediatric CVADs fail before completion of treatment due to infection, thrombosis, dislodgement and occlusion. This is frequently attributed to inadequate securement and dressing of the device, however high quality research evaluating pediatric CVAD securement innovation to prevent CVAD failure is scarce. This study aimed to establish the feasibility of a definitive randomized control trial (RCT) examining the effectiveness of current and new technologies to secure CVADs in pediatrics.

Design Single centre, parallel group, superiority, pilot RCT.

Setting Anesthetic and intensive care departments of a tertiary pediatric hospital

Subjects One hundred and eighty pediatric patients with non-tunneled CVAD

Interventions Participants were randomized to receive CVAD securement via standard care (bordered polyurethane dressing, with prolene sutures, chlorhexidine gluconate disc), tissue adhesive (Histoacryl®) in addition to standard care; or integrated dressing securement (SorbaView SHIELD®, with prolene sutures and CHG disc). Outcomes: Primary: Feasibility (including effect size estimates, acceptability); CVAD failure, CVAD complications; Secondary: individual CVAD complications, skin damage, dressing performance and product cost.

Measurements and main results Feasibility criteria were achieved as recruitment occurred with acceptable eligibility, recruitment, missing data and attrition rates, as well as good protocol adherence. Family members and staff reported comparable levels of acceptability between study arms, however tissue adhesive was reported as the most difficult to apply. Overall, 6% of CVADs failed, including 6% (3/54; incident rate [IR] 13.2 per 1,000 catheter days) standard care, 2% (1/56; IR 3.65 per 1,000 catheter days) integrated, and 8% (5/59; 25.0 per 1,000 catheter days) tissue adhesive.

Conclusion It is feasible to conduct an efficacy RCT of the studied interventions. Further research is required to definitively identify clinical, cost-effective methods to prevent CVAD failure by examining new dressing and securement technologies and techniques.

Clinical trial registration: ACTRN12615000977572

Keywords: vascular access, central; dressing; site care; evidence-based care; pediatrics, critical care

INTRODUCTION

Over 50% of children admitted to pediatric critical care units require a central venous access device (CVAD) for therapy administration, including inotropes, nutrition and complex sedation (1). Over the past 20 years, there has been increasing focus on the prevention of CVAD-associated bloodstream infection (BSI), due to its significant sequelae on morbidity, mortality, and healthcare resources (2, 3). Recent literature has highlighted other sources of harm associated with CVAD dysfunction, with 25% of pediatric CVADs failing prior to completion of therapy, due to mechanical, thrombotic and infective origins, resulting in treatment disruption (4, 5).

Effective CVAD dressing and securement is central to the prevention of many causes of CVAD complication. Polyurethane dressings are used to protect the insertion site from external contaminants, with additional chlorhexidine-impregnated products (either via disc or impregnated gel) demonstrated to significantly reduce the rate of CVAD-associated BSI (Risk Ratio [RR] 0.51, 95% confidence interval [CI] 0.33 to 0.78), by preventing extra-luminal colonization of the CVAD insertion site (6). Additional securement devices, such as sutures, are used to minimize movement of the catheter from its optimal position. CVAD dislodgement is an increasingly prominent complication in pediatric critical care units, likely due to light sedation and early mobilization becoming the standard of care to facilitate long term recovery (7).

Within the changing pediatric critical care environment, innovation is necessary to identify effective CVAD securement products. Tissue adhesive (TA), or medical grade superglue, provides a physical barrier against microbial entry, promotes hemostasis and offers adhesion between the catheter and insertion site. TA has been successfully trialled with a reduction in failure and complication rates reported in adult intensive care (8), and for other types of CVADs (i.e., tunneled, cuffed CVADs, peripherally inserted central catheters) in pediatric patients (9, 10). TA has not been tested in pediatric critical care, where it may be of greatest value. Similarly, integrated securement and dressing products (ISD) have been developed as reinforced polyurethane products, with increased dressing border

integrity and device security (9, 11). It is not known whether these new products are effective at reducing CVAD failure and complication, in pediatric critical care. The aim of this study was to evaluate the feasibility of an efficacy trial comparing innovations in non-tunneled CVAD security, (using pre-defined criteria for recruitment, retention, protocol fidelity, satisfaction and sample size estimates).

MATERIALS AND METHODS

Design

A single center, parallel group, pilot randomized controlled trial (RCT) in pediatric patients with non-tunneled CVADs who were admitted to a Pediatric Intensive Care Unit (PICU). The trial was prospectively registered with the Australian Clinical Trials Registry (ACTRN12615000977572) and the protocol was published (12).

Study setting

The trial was conducted within the anaesthetic department and PICU at the Queensland Children's Hospital, Australia. The hospital is a tertiary level, specialist pediatric teaching hospital, which provides full-spectrum services to children and young people from birth to 18 years of age.

Participants and sample size

Eligibility criteria were: age less than 18 years of age, requiring the insertion of a non-tunnelled, percutaneously inserted CVAD (jugular, subclavian or femoral) that would remain *in situ* for greater than 24 hours, PICU admission. Patients were ineligible if any other type of intravascular device was to be inserted (e.g., peripherally inserted central catheter), current blood stream infection (BSI) at recruitment, were receiving extracorporeal membrane oxygenation recruitment, CVAD insertion site was diseased, burned, scarred, torn, or extremely diaphoretic, patients had a known allergy to any of the study products, or had previously participated in the study within the current hospital admission.

The enrolment plan included sixty subjects per intervention group (total n=180), with patients eligible for participation multiple times (i.e., participation per CVAD). Sample sizes were based on requirements for feasibility testing and informing effect size estimates for the efficacy trial (13, 14).

Intervention

Participants were randomly assigned to receive one of three CVAD securement procedures (displayed in Figure 1):

1. *Standard care*: Bordered polyurethane dressing (Tegaderm 1655 [8.9 x 11.5cm] or 1614 [6 x 7cm] [depending on patient size]; 3M, St Paul).
2. *Tissue adhesive (TA)*: TA (Histoacryl; B Braun, Melsungen; two drops applied at the CVAD insertion wound, and under each CVAD wing), and bordered polyurethane dressing (Tegaderm 1655 [8.9 x 11.5cm] or 1614 [6 x 7cm] [depending on patient size]; 3M, St Paul).
3. *Integrated securement and dressing (ISD)*: ISD (SorbaView SHIELD SV430UDT [9.53 x 11.75 cm] or SV254 [6.35 x 10.16 cm] [depending on patient size]; Centurion Medical Products, Williamston).

<insert Figure 1>

To ensure safety as per existing hospital policy, all participants received primary device security via prolene suture (Ethicon, Somerville), and infection prevention via CHG disc (Biopatch; Johnson & Johnson, Brunswick). A GripLok (3200S, Tidi Products, Neenah) was used in all groups at attachment to the administration sets, to reduce drag.

Outcomes

The primary outcomes were feasibility of a definitive efficacy trial of CVAD securement in pediatric critical care, and CVAD failure. Feasibility was determined through composite analysis eligibility, recruitment, retention and attrition, protocol adherence, missing data, parent and healthcare staff ratings of product of satisfaction and acceptability, and sample size calculations based on effect size estimates (14, 15). Parent/caregiver and health care staff (nurses, physicians) satisfaction and acceptability of the securement products was determined using a 0-10 numeric rating scale of increasing satisfaction, at CVAD insertion and removal. CVAD failure was defined as cessation of device function prior to completion of therapy(4).

Secondary outcomes were CVAD complications, dressing performance (durability), skin complications and serious adverse events. CVAD complications were: (i) CVAD-associated BSI (16), (ii) local skin infection (16), (iii) venous thrombosis (radiologically confirmed), (iv) partial or complete CVAD dislodgement (17), (v) partial or complete occlusion (18), and (vi) CVAD breakage (19). Diagnoses of CVAD-associated BSI and venous thrombosis were made by an independent, blinded infectious disease or radiologist specialist respectively. Dressing performance was measured through the dwell time of the first dressing application and requirement for non-routine (i.e. every seven days (20)) dressing change. Skin complications included pressure injuries, dermatitis and mechanical injuries (e.g., skin tear and blisters) (21). We initially planned to compare cost-effectiveness, however this was not completed due to resource availability, so cost estimates were of direct product costs, only.

Study procedures

Research nurses (ReNs) completed daily screening of patients who were either in the PICU or booked for PICU admission after a cardiac procedure, obtained informed consent, and accessed the allocated randomization. Randomization was web-based via Griffith University (<https://www151.griffith.edu.au/random>), and generated in a 1:1:1 ratio for the study groups, stratified

by CVAD site (jugular vs other), including randomly varied block sizes, with concealment until after consent.

The ReN provided the CVAD inserting clinician with a prepared study pack, including all necessary products. Extensive education and user guides were provided via multimedia to clinicians to ensure consistency and protocol adherence for initial and subsequent applications. TA was applied only on insertion by the CVAD inserting clinician, with no further application at later dressing changes, since otherwise build up occurs on the catheter body (9-11). PICU nursing staff changed all CVAD dressing and securements weekly or as clinically indicated (i.e., if no longer clean, dry and intact), with additional dressing changes and reinforcements permitted and (e.g. tape) recorded.

Data were prospectively collected into REDCap (Research Electronic Data CAPture ;<http://project-redcap.org/>), during daily patient visits by the ReN. Follow up was until four weeks after insertion, study withdrawal, removal of the CVAD, or hospital discharge. This included data on outcomes, with additional demographic and clinical data collected to describe the participant group, enable comparisons to inform generalisability, and characteristics that are known to increase the risk of CVAD failure (19, 22-27).

CVAD procedures

Other than the CVAD securement interventions, CVADs were inserted and managed as per local clinical policy (28) and international clinical practice guidelines (20). Standardized CVAD practices included maximum sterile procedures throughout insertion, uncoated polyurethane catheters (Cook® [Cook Medical, Bloomington] and Arrow® [Teleflex. Morrisville]), skin and connector decontamination with 2% CHG in alcohol, ultrasound (as per clinician choice), and neutral needleless connectors (N-Pulse; TUTA Healthcare, Victoria) during therapy. The CVAD inserter selected site (e.g. jugular, subclavian), size and number of lumens, based on predicted patient needs, vessel availability, and insertion-associated risks. Decisions regarding blood and CVAD tip cultures, and ultrasound for identification of symptomatic venous thrombosis were requested by the clinical team.

Data analysis

De-identified data were transferred to Stata 15 for analysis. The unit of analysis was the CVAD. Prior to analysis, data cleaning of outlying figures, missing, and implausible data were undertaken, and a random 5% sample of primary and secondary outcome data re-entered and checked. Descriptive statistics were used to ascertain the primary outcome of feasibility, with predetermined acceptability criteria as being (i) > 80% of patients screened will be eligible, (ii) > 80% will agree to enrol, (iii) > 90% will receive the allocated intervention and (iv) < 5% of enrolled patients will be lost to follow-up. Acceptability was compared between treatment groups using appropriate statistics, relevant to data distribution. All randomized patients were analyzed on an intention-to-treat basis, and baseline parameters were compared using clinical criteria. Incidence Rates (IRs) and Incident Rate Ratios (IRRs) of CVAD failure were used to summarize the impact of each securement program, with group differences evaluated by 95% CIs and p-values. Kaplan-Meier survival curves (with log rank test) were used to compare failure over time between groups. Secondary endpoints including individual CVAD complications, dressing performance, and skin complications were compared between groups using parametric or nonparametric test as appropriate. Univariable regression (Cox) was performed to test the effect of patient and device variables associated with CVAD failure. Variables were re-categorized to suit regression analysis, as necessary (e.g. to eliminate categories with <20 cases). P values <0.05 were considered statistically significant. Costs were calculated using Queensland Health purchase prices for dressing and securements in Australian dollars (2016).

Ethics

Approval to undertake the trial was received from both the Children's Health Services Queensland (HREC/13/QLD/181), and the Griffith University (NRS/10/14/HREC) Human Research Ethics Committees. Written informed consent was gained from parents or legal guardians, with the use of either an immediate [prospective] or a deferred [retrospective] consent process.

RESULTS

Participation, feasibility and demographics

Between February and August 2016, 282 subjects (impending CVAD insertions) were screened, with 103 not meeting the inclusion and exclusion criteria, however this was mainly due to 70 potential participants who were missed due to CVAD insertion after ReN work hours. No families refused to participate. After randomization one CVAD was not successfully inserted, and three subjects were accidentally double randomized (these were managed as per the initial randomization). One patient withdrew from the study due to extreme diaphoresis, no CVAD was lost to follow up. The subject flow is displayed within the CONSORT Flow Figure 2. As displayed in Supplementary Table 1, the composite of feasibility outcomes was met. Protocol adherence was high, with 93% of CVADs receiving the allocated intervention throughout the study, and no missing data for primary or secondary outcomes.

<insert Figure 2>

<insert Supplementary Table 1 (online only)>

Staff reported reduced mean acceptability of applying the TA (5.4/10; standard deviation (SD) 2.3), in comparison to standard care (6.2/10; SD 2.3) and ISD (6.2/10; SD 1.9; $p=0.023$). There were no differences in all other assessments of acceptability by staff, including dressing change and dressing removal. Parents and caregivers reported higher mean satisfaction with the ISD (9.4/10; SD 1.7), in comparison to standard care (8.2/10; SD 2.7) and TA (8.2/10; SD 2.5).

In total, 702 catheter days were studied. Participants were on average 38 months old (IQR 33-61), undergoing a cardiac surgical procedure (126/174; 72%), with a median PIM3 of 0.5 (IQR 0.3-1.4) (Supplementary Table 1). The majority of CVADs were placed in the operating theatre (116/169; 69%), in the internal jugular (99/169; 59%) or femoral veins (68/169; 40%), and with ultrasound guidance (99/112; 88%) (Table 1). Overall, the majority of clinical characteristics were distributed evenly between the study groups, however others had greater than 10% imbalance (e.g., gender, CVAD placement, location inserted).

<insert Supplementary Table 2 (online only)>

CVAD failure and complications

Nine CVADs (9/169; 5.3%) failed during treatment. The highest incidence and incidence rate (IR) of failure occurred in the TA group (8%; IR 25 per 1,000 catheter days [Incident Rate Ratio, IRR compared to controls 1.89, 95% confidence interval, CI 0.37-12.2], see Table 1). In the ISD group, failure was IR 3.65, IRR 0.28 (95% CI 0.01-3.46) compared to controls. These findings were consistent over time (Figure 3). CVAD dislodgement was the most common overall complication (6/169; 4%), but did not occur in the ISD group. While three CVADs were removed on suspicion of CVAD-associated BSI, this diagnosis was only confirmed in one participant (*pseudomonas aeruginosa*; standard care). No CVAD breakage occurred, and the average CVAD dwell time was similar between groups. Skin complications, including rash, blistering and bruising occurred in seven participants (4%). No allergic dermatitis reactions, or itchiness occurred within the study

<insert Table 1>

<insert Figure 3>

Univariate Cox regression demonstrated no clinical variables to be significantly associated with risk of CVAD failure (as defined as $p < 0.05$).

Dressing and securement performance

The overall dressing and securement performances are displayed in Table 2. Each of the intervention securement products was associated with increased direct purchasing costs, in comparison to standard care. For subjects requiring a dressing change during CVAD dwell, mean first dressing dwell time was lower for standard care (2.5 days [IQR 1.6-4.8]), in comparison to ISD (4.8 days [1.4-8.0]) and TA (5.4 days [2.1-6.7]). There was also reduction in the need for dressing changes in each of the intervention groups, in comparison to standard care. Within the TA group, dressing changes due to bleeding were reduced (8%) in comparison to standard care 20% and ISD 11%. There was use of additional securement products across the study arms, including non-sterile tapes.

<insert Table 2>

DISCUSSION

We report the results of the first RCT conducted in PICU to inform effective CVAD securement. Employing robust methods, including a published and registered protocol, we have demonstrated that a large-scale efficacy trial of CVAD securement is feasible, meeting the *a priori* composite feasibility criteria surrounding recruitment, attrition, and protocol adherence. While 70 potential participants were missed for recruitment, this is likely to be improved with increased resourcing. The CVAD failure rate reduction between the standard care and ISD group, estimates a 35% relative reduction in failure may be confirmed in future trials, especially in decreasing CVAD dislodgement, further strengthening efficacy trial feasibility. As recommended by the UK's Medical Research Council's Developing and evaluating complex interventions framework (29), this project has provided much needed feasibility data for these future efficacy trials. Additional innovations also require testing, since the rapidly changing PICU environment continues to see emerging technologies (e.g., subcutaneous CVAD anchors (30)).

Despite our study cohort being short-term CVADs (mean duration 2.2 days), 5.3% failed prior to the completion of therapy. This level of failure is similar to rates recently reported in adult critical care settings (31), and demonstrates a serious health and economic burden for PICUs worldwide. CVAD failures cause disruptions to treatment during PICU admission, and may have serious effects on patient morbidity and mortality (32). While the PICU has previously targeted clinical improvements to prevent CLABSI (3, 33), other significant causes of CVAD-associated harm, such as catheter dislodgement, have yet to receive similar innovation and attention.

The two interventions tested have biological and mechanical plausibility to prevent many causes of CVAD failure and complication, in comparison to bordered polyurethane dressing. Medical-grade cyanoacrylate glues, or TA, has been demonstrated in *in vitro* and clinical studies to improve attachment of vascular access devices, and to inhibit microbial growth, in comparison to current

polyurethane dressings (34, 35). Modern ISDs are considered the 'next generation' of dressing products, reducing procedural complexity associated with applying multiple separate securement devices, and involve an adhesive component holding below and above the CVAD (36). These characteristics suggest ISDs would perform well to minimize CVAD accidental dislodgement during movement.

As expected in a pilot trial, the CVAD securement innovations tested did not clinically or statistically impact CVAD failure rates, but some procedural results were demonstrated. Despite education resources, and one-on-one support from ReNs, CVAD inserting clinicians found TA difficult to apply, especially during the early phases of the trial, and this added complexity to an already difficult CVAD insertion procedure. TA may have a role in the promotion of hemostasis at the CVAD insertion wound, as evident in the prolonged first dressing dwell, reduced need for non-routine dressing changes due to bleeding, and previous studies on other CVAD types (9, 10). If some of the practical issues around the application of TA were rectified, the hemostatic properties may be of benefit for some specific patient groups, such as patients recently therapeutically anti-coagulated for cardiac procedures (9).

Despite improvements in hemostasis within the TA group, there was still a high dressing failure rate within the overall cohort, with only 5% of CVAD dressing change procedures initiated due to routine requirements; 95% of dressing changes were initiated due to dressing disruption, primarily due to dressing edges lifting. Timsit, Bouadma (37), in their secondary analysis of a CVAD dressing RCT in adult critical care previously highlighted the three-fold increased risk for BSI associated with dressing disruption within critical care, highlighting that innovation in this area is warranted. Additionally, there is significant risk associated with accidentally dislodging CVADs during dressing change procedure on a non-compliant, recently anesthetised child (9, 10). Acceptability of the ISD was high, and parents reported high levels of satisfaction associated with the product. However, further study of TA and other innovations to economically promote CVAD security, and wound hemostasis, is necessary.

Although both interventions tested had a higher direct purchasing price in comparison to standard care, the potential overall savings associated with a reduction in CVAD failure, complications and repetitious dressing changed procedures are considerable (38, 39). An additional immediate cost would be warranted, if these products were to reduce these complications, and could be safely incorporated into PICU management. Cost-effectiveness has yet to be demonstrated, and further research is necessary.

While using high quality methods, our trial has some limitations. The study was undertaken in a single, tertiary referral pediatric hospital, limiting generalizability. However, a variety of insertion sites and clinical areas were included, increasing generalizability. Decisions regarding CVAD insertion sites, lumens and size were made by the inserting clinician, not by study staff, decreasing standardization within underlying practice. The impact of imbalance in risk factors between study groups is relatively greater in pilot trials (due to lower sample size), and some imbalances between the groups were seen. Clinicians, participants, family members, and ReN were not blinded to the intervention, due to obvious visual differences. However, it is unlikely this would have influenced clinical decision-making. The data analyst was blinded for analysis, and a blinded infectious disease and radiological physicians determined outcomes for the infectious and thrombotic complication reported, thus avoiding potential biases.

Conclusions

CVAD complications and failure remain problematic within PICUs. Innovation in CVAD security is warranted, to ensure the safety of children relying on CVAD function during critical illness. An efficacy trial of CVAD securements in PICU is feasible, provided there are adequate resources to recruit and follow up patients, and education of clinicians regarding practice changes. Further research is necessary to definitively identify clinical, cost-effective methods to prevent CVAD failure within pediatric critical care.

Acknowledgments

We would like to thank the staff of the PICU and anaesthetic departments of the Queensland Children's Hospital for their support and participation within the study. We would also like to thank the children and parents who participated in the study.

Figure Legends

Figure 1. CVAD securement groups: a) Standard care. b) Tissue adhesive (TA). c) Integrated securement and dressing (ISD)

Figure 2. CONSORT Flow chart of study participation (Unit of analysis: CVAD)

Figure 3. Kaplan Meier survival curve of CVAD failure by study groups

References:

1. Ullman AJ, Kleidon T, Cooke M, et al. Road map for improvement: Point prevalence audit and survey of central venous access devices in paediatric acute care. *J Paed Child Health* 2017;53(2):123-130.
2. Bezzio S, Scolfaro C, Broglia R, et al. Prospective incidence study of bloodstream infection in infants and children with central venous catheters after cardiac surgery in Italy. *Infect Control Hosp Epidemiol* 2009;30(7):698-701.
3. Gilbert RE, Mok Q, Dwan K, et al. Impregnated central venous catheters for prevention of bloodstream infection in children (the CATCH trial): a randomised controlled trial. *Lancet* 2016;387(10029):1732-1742.
4. Ullman AJ, Marsh N, Mihala G, et al. Complications of central venous access devices: a systematic review. *Pediatrics* 2015;136(5):e1331-1344.
5. Rickard CM, Ullman AJ. Bloodstream infection and occlusion of central venous catheters in children. *Lancet Infect Dis* 2018;18(8):815-817.
6. Ullman AJ, Cooke ML, Mitchell M, et al. Dressings and securement devices for central venous catheters (CVC). *Cochrane Database Syst Rev* 2015;9:Cd010367.
7. Choong K, Awladthani S, Khawaji A, et al. Early exercise in critically ill youth and children, a preliminary evaluation: The wEECYCLE pilot trial. *Ped Crit Care Med* 2017;18(11):e546-e554.
8. Rickard CM, Edwards M, Spooner AJ, et al. A 4-arm randomized controlled trial of solutions for jugular central venous access device securement in 221 cardiac patients. *J Crit Care* 2016;36:35-42.
9. Kleidon TM, Ullman AJ, Gibson V, et al. A pilot randomized controlled trial of novel dressing and securement techniques in 101 pediatric patients. *J Vasc Interv Radiol* 2017;28(11):1548-1556.e1541.
10. Ullman A, Kleidon T, Gibson V, et al. Innovative dressing and securement of tunneled central venous access devices in pediatrics: a pilot randomized controlled trial. *BMC Cancer* 2017;17(1):595.

11. Chan RJ, Northfield S, Larsen E, et al. Central venous Access device SeCurement And Dressing Effectiveness for peripherally inserted central catheters in adult acute hospital patients (CASCADE): a pilot randomised controlled trial. *Trials* 2017;18(1):458.
12. Ullman AJ, Kleidon T, Gibson V, et al. Central venous Access device SeCurement And Dressing Effectiveness in paediatrics: protocol for randomised controlled trials. *BMJ Open* 2016;6(6).
13. Hertzog M. Considerations in determining sample size for pilot studies. *Res Nurs Health* 2008;31:180-191.
14. Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. *J Eval Clin Pract* 2004;10(2):307-312.
15. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. *BMC Med Res Meth* 2010;10(1):1.
16. Centers for Disease Control and Prevention and National Healthcare Safety Network. July 2013 CDC/NHSN Protocol Clarifications. In: Centers for Disease Control and Prevention, editor.; 2013.
17. Yamamoto A, Solomon J, Soulen M, et al. Sutureless securement device reduces complications of peripherally inserted central venous catheters. *J Vasc Interv Radiol* 2002;13(1):77-81.
18. Goossens GA, De Waele Y, Jerome M, et al. Diagnostic accuracy of the Catheter Injection and Aspiration (CINAS) classification for assessing the function of totally implantable venous access devices. *Support Care Cancer* 2016;24(2):755-761.
19. Frattino G, Molinari AC, Parodi S, et al. Central venous catheter-related complications in children with oncological/hematological diseases: an observational study of 418 devices. *Ann Oncol* 2005;16(4):648-654.
20. O'Grady N, Alexander M, Burns L, et al. Guidelines for the prevention of intravascular catheter-related infections. *Clinical Infectious Diseases* 2011;52(9):1087-1099.
21. Broadhurst D, Moureau N, Ullman AJ. Management of central venous access device-associated skin impairment: An evidence-based algorithm. *J Wound Ostomy Continence Nurs* 2017;44(3):211-220.

22. Cecinati V, Brescia L, Tagliaferri L, et al. Catheter-related infections in pediatric patients with cancer. *Eur J Clin Microbiol Infect Dis* 2012;31(11):2869-2877.
23. Reichman D, Greenberg J. Reducing surgical site infections: a review. *Rev Obst Gyn* 2009;2(4):212-221.
24. Advani S, Reich NG, Sengupta A, et al. Central line-associated bloodstream infection in hospitalized children with peripherally inserted central venous catheters: extending risk analyses outside the intensive care unit. *Clin Infect Dis* 2011;52(9):1108-1115.
25. Robinson JL, Casey LM, Huynh HQ, et al. Prospective cohort study of the outcome of and risk factors for intravascular catheter-related bloodstream infections in children with intestinal failure. *J Parenter Enteral Nutr* 2013.
26. Lorente L, Huidobro MS, Martin MM, et al. Accidental catheter removal in critically ill patients: a prospective and observational study. *Crit Care* 2004;8(4):R229-233.
27. Jumani K, Advani S, Reich NG, et al. Risk factors for peripherally inserted central venous catheter complications in children. *JAMA Ped* 2013;167(5):429-435.
28. Children's Health Services. CVAD Insertion and Management. In. Brisbane: Queensland Government; 2014.
29. Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating complex interventions: the new Medical Research Council guidance. *BMJ* 2008;337:a1655.
30. Goossens GA, Grumiaux N, Janssens C, et al. SecurAstaP trial: securement with SecurAcath versus StatLock for peripherally inserted central catheters, a randomised open trial. *BMJ Open* 2018;8(2).
31. Takashima M, Schults J, Mihala G, et al. Complication and failures of central vascular access device in adult critical care settings. *Crit Care Med* 2018.
32. Athale UH, Siciliano S, Cheng J, et al. Central venous line dysfunction is an independent predictor of poor survival in children with cancer. *J Pediatr Hematol Oncol* 2012;34(3):188-193.
33. Edwards JD, Herzig CT, Liu H, et al. Central line-associated blood stream infections in pediatric intensive care units: Longitudinal trends and compliance with bundle strategies. *Am J Infect Control* 2015;43(5):489-493.

34. Simonova G, Rickard CM, Dunster KR, et al. Cyanoacrylate tissue adhesives - effective securement technique for intravascular catheters: in vitro testing of safety and feasibility. *Anaesthesia Intensive Care* 2012;40(3):460-466.
35. Rickard CM, Marsh N, Webster J, et al. Dressings and securements for the prevention of peripheral intravenous catheter failure in adults (SAVE): a pragmatic, randomised controlled, superiority trial. *Lancet* 2018;392(10145):419-430.
36. Rickard CM, Marsh NM, Webster J, et al. Peripherally InSerted CEntral catheter dressing and securement in patients with cancer: the PISCES trial. Protocol for a 2x2 factorial, superiority randomised controlled trial. *BMJ Open* 2017;7(6):e015291.
37. Timsit JF, Bouadma L, Ruckly S, et al. Dressing disruption is a major risk factor for catheter-related infections. *Crit Care Med* 2012;40(6):1707-1714.
38. Wilson MZ, Rafferty C, Deeter D, et al. Attributable costs of central line-associated bloodstream infections in a pediatric hematology/oncology population. *Am J Infect Control* 2014;42(11):1157-1160.
39. Ullman AJ, Kleidon T, Cooke M, et al. Substantial harm associated with failure of chronic paediatric central venous access devices. *BMJ Case Reports* 2017;doi:10.1136/bcr-2016- 218757.

Supplementary Table 1. Feasibility outcomes

Feasibility criteria	N (%)	Feasibility criteria met
≥ 80% of screened patients will be eligible:	249/282 (88%)	Yes
≥ 80% will agree to enrol	179/179 (100%)	Yes
>90% recruited patients will receive allocated treatment	161/179 (93%)	Yes
<5% of patients will be lost to follow up	0	Yes

Supplementary Table 2. Participant and CVAD characteristics (N=174)

Variables		Control	ISD	TA	Total
Group size ^a		58 (33)	57 (33)	59 (34)	174 (100)
Participant characteristics					
Age	Birth to 2 months	18 (31)	15 (26)	16 (27)	49 (28)
	3 months to 11 months	16 (28)	13 (23)	22 (37)	51 (29)
	1 to 4 years	8 (14)	14 (25)	8 (14)	30 (17)
	5 to 9 years	11 (19)	9 (16)	7 (12)	27 (16)
	10 years or older (≤18)	5 (9)	6 (11)	6 (10)	17 (10)
Sex	Male	33 (57)	26 (46)	32 (54)	91 (52)
PIM3 ^b		0.5 (0.3-1.4)	0.4 (0.3-1.2)	0.5 (0.3-1.5)	0.5 (0.3-1.4)
Skin integrity (at baseline)	Good	40 (69)	48 (84)	45 (76)	133 (76)
	Fair	17 (29)	9 (16)	13 (22)	39 (22)
	Poor	1 (2)	0 (0)	1 (2)	2 (1)
Skin type	White	44 (76)	49 (86)	45 (76)	138 (79)
Comorbidities	None	32 (55)	31 (54)	36 (61)	99 (57)
	One	22 (38)	20 (35)	19 (32)	61 (35)
	Two	4 (7)	6 (11)	4 (7)	14 (8)
Diagnosis	Cardiac surgical	43 (74)	42 (74)	41 (69)	126 (72)
	Medical	11 (19)	10 (18)	14 (24)	35 (20)
	Surgical	2 (3)	3 (5)	3 (5)	8 (5)
	Oncology	2 (3)	2 (4)	1 (2)	5 (3)
Infection at recruitment		7 (12)	7 (12)	6 (10)	20 (11)
Leucocytes low ^c at recruitment		25 (69)	34 (81)	30 (79)	89 (77)
ECMO during study		4 (8)	5 (9)	2 (3)	11 (7)
Actively cooled/warmed during study		28 (52)	34 (61)	36 (61)	98 (58)
Diaphoretic during study		35 (66)	33 (61)	34 (62)	102 (63)
Confused, agitated or drowsy at completion		11 (20)	15 (27)	17 (29)	43 (25)
Ventilated / intubated at completion		6 (11)	8 (14)	9 (15)	23 (14)
Mobilisation level (at best)	Independent / appropriate	9 (17)	9 (16)	2 (3)	20 (12)
	Mobilising with assistance	10 (19)	8 (14)	10 (17)	28 (17)
	Able to move in bed	10 (19)	14 (25)	7 (12)	31 (18)
	Unable to mobilise	25 (46)	25 (45)	40 (68)	90 (53)
CVAD characteristics					
Placement	Internal jugular	35(65)	36 (64)	28 (47)	99 (59)
	Femoral	19 (35)	20 (36)	29 (49)	68 (40)
	Subclavian	0 (0)	0 (0)	2 (3)	2 (1)
CVAD gauge	4.0 Fr	12 (22)	15 (27)	17 (29)	44 (26)
	4.5 Fr	1 (2)	3 (5)	1 (2)	5 (3)
	5.0 Fr	22 (41)	29 (52)	25 (42)	76 (45)
	5.5 Fr	15 (28)	9 (16)	14 (24)	38(22)
	≥7.0 Fr	4 (7)	0 (0)	2 (3)	6 (4)
Number of lumens	Dual	2 (4)	5(9)	1 (2)	8 (5)
	Triple	51 (94)	51 (91)	57 (97)	159 (94)
	Quad	1 (2)	0 (0)	1 (2)	2 (1)
Inserted by	Anaesthetist	37 (70)	41 (73)	44 (75)	122 (73)
	PICU Registrar	12 (23)	9 (16)	11 (19)	32 (19)
	PICU Consultant	4 (8)	6 (11)	4 (7)	14 (8)
Location inserted	Operating theatre	33 (61)	42 (75)	41 (69)	116 (69)
	PICU	21 (39)	14 (25)	17 (29)	52 (31)
	Radiology	0 (0)	0 (0)	1 (2)	1 (1)
Multiple insertion attempts		3 (12)	3 (13)	5 (21)	11 (15)

Ultrasound guidance used		31 (84)	34 (89)	34 (92)	99 (88)
Treatment (at baseline)	Continuous fluids	43 (74)	41 (72)	44 (75)	128 (74)
	Inotropes	37 (64)	28 (49)	34 (58)	99 (57)
	Sedation/ analgesia	52 (90)	53 (93)	56 (95)	161 (93)
	Blood products	29 (50)	23 (40)	23 (39)	75 (43)
	Parenteral nutrition	3 (5)	3 (5)	4 (7)	10 (6)
	Antibiotics	49 (84)	54 (95)	54 (92)	157 (90)

Frequencies and column percentages shown unless otherwise indicated; percentages calculated using the number of non-missing observations as denominator; ^a row percentages shown; ^b median and interquartile range (as 25th-75th percentiles) shown; ^c low = below 1,000 per microlitre; CVAD=central venous access device; ECMO=extracorporeal membrane oxygenation; Fr=French; ISD = integrated securement and dressing product; TA = tissue adhesive; PICU=pediatric intensive care unit;

a.

b.

c.

Figure 1. CVAD securement groups: a) Standard care. b) Tissue adhesive (TA). c) Integrated securement and dressing (ISD)

At risk

control	54	50	34	26	21	15	14	12
ISD	56	51	37	22	18	17	15	11
TA	59	51	33	23	19	15	11	8

Table 1. CVAD failure and complications (N=169)

Variables	Control	ISD	TA	<i>p</i>
Group size ^a	54 (32)	56 (33)	59 (35)	
CVAD removal due to				
CVAD failure	3 (6)	1 (2)	5 (8)	0.300 ^b
Treatment completed: no complications	44 (81)	49 (88)	51 (86)	
Treatment completed: with complications	3 (6)	6 (11)	1 (2)	
Treatment incomplete: with complications	3 (6)	1 (2)	5 (8)	
Patient deceased	3 (6)	0 (0)	1 (2)	
Discharged with device: no complications	1 (2)	0 (0)	1 (2)	
CVAD failure IR (1,000 catheter days, 95% CI)	13.2 (4.25- 40.8)	3.65 (0.51- 25.9)	25.0 (10.4- 60.0)	
CVAD failure IRR (1,000 catheter days, 95% CI)	referent	0.28 (0.01- 3.46)	1.89 (0.37- 12.2)	0.174 ^c
CVAD complications ^d				
Dislodgement (complete)	2 (4)	0 (0)	0 (0)	
Dislodgment (partial)	1 (2)	0 (0)	3 (5)	
Suspected CVAD-associated BSI	1 (2)	1 (2)	1 (2)	
Confirmed CLABSI	1 (2)	0 (0)	0 (0)	
Thrombosis	1 (2)	1 (2)	1 (2)	
Local infection	0 (0)	1 (2)	0 (0)	
Occlusion (complete)	0 (0)	1 (2)	0 (0)	
Other	1 (2)	2 (4)	1 (2)	
Unknown	1 (2)	1 (2)	0 (0)	
Skin complications				
Any	2 (4)	3 (5)	2 (3)	
Tear	1 (2)	2 (4)	1 (2)	
Rash	1 (2)	1 (2)	1 (2)	
Blister	0 (0)	2 (4)	0 (0)	
Bruising	0 (0)	0 (0)	1 (2)	
Serious adverse events				
Death	3	0	1	
Dwell time (days) ^e	2.69 (5.09)	2.23 (4.85)	2.18 (3.89)	
Catheter days (total)	228	274	200	

Frequencies and column percentages shown unless otherwise indicated; percentages calculated using the number of non-missing observations as denominator; ^a row percentages shown; BSI = bloodstream infection; ^b Fisher's exact test; ^c log-rank test; CVAD = central venous access device; ^d participants could have multiple CVAD complications during study ^e median and inter-quartile range; ISD = integrated securement product; TA = tissue adhesive

Table 2. Dressing and securement performance

Variables	Control	ISD	TA
Group size	54 (32)	56 (33)	59 (35)
Initial application product purchase costs^a	\$0.06-0.24	+\$3.53	+\$11.80
Patients with a dressing/securement change^b	16 (28)	12 (21)	8 (14)
Number of additional dressing/securements used (excluding 1st)	38	27	8
Life of first dressing, days (n=36)^c	2.5 (1.6-4.8)	4.8 (1.4-8.0)	5.4 (2.1-6.7)
Life of first dressing $\geq$ 7 days (n=36)^b	1 (6)	5 (42)	2 (25)
Reasons for dressing changes^{b,c}			
Lifting (n=93)	17 (41)	17 (44)	5 (38)
Bleeding (n=92)	8 (20)	4 (11)	1 (8)
Leakage (n=92)	3 (7)	3 (8)	0 (0)
Routine (n=92)	2 (5)	2 (5)	1 (8)
Sweating (n=92)	2 (5)	2 (5)	0 (0)
Allergy (n=92)	0 (0)	1 (3)	0 (0)
Other (n=92)	3 (7)	5 (13)	1 (8)
Additional securing devices (at any time during study; n=165)^b			
Strips of non-sterile tape	2 (4)	2 (4)	3 (5)
Bordered dressing	1 (2)	2 (4)	0 (0)
TA	1 (2)	2 (4)	0 (0)
Additional randomised study product	0 (0)	0 (0)	1 (2)
Foam	1 (2)	0 (0)	0 (0)
Sterile gauze	1 (2)	0 (0)	0 (0)
Other	4 (8)	1 (2)	1 (2)

^a in Australian dollars according to local hospital prices 2016; ^b percentage and % shown; ^c median and inter-quartile range (as 25th/75th percentiles) shown; ^c multiple answer question